- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX)
This study is testing a new combination of treatments for advanced bowel cancer. It's looking at whether adding a drug called D,L-methadone to standard chemotherapy (mFOLFOX6) can help control the cancer, and how safe it is.
For: Patients with advanced · histologically confirmed · metastatic colorectal carcinomaGermany - Ongoing, recruitingTherapeutic use (Phase IV)
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS
This study looks at how long people with a certain type of pancreatic cancer live after receiving treatment. It specifically focuses on real-world experiences with common chemotherapy drugs before surgery.
For: Resectable pancreatic adenocarcinoma with risk factorsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
For: Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionPoland · Hungary · Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
This study looks at new treatments for a type of head and neck cancer that has come back or spread. It compares an immunotherapy drug called pembrolizumab, alone or with another drug called epacadostat, against a standard treatment.
For: Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapiesPortugal · Spain - Active not recruitingPHASE3
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
This study looks at a new medicine called zolbetuximab, combined with chemotherapy, for adults with advanced stomach cancer. It aims to see if this combination works better than chemotherapy alone to stop the cancer from getting worse.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Australia · Belgium - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39)
This study looks at a new way to treat stomach and gullet cancer after surgery. Half of the patients get less chemotherapy, and the other half get the usual amount. We want to see if less treatment is just as good, safer, and helps people feel better.
For: Low risk of disease recurrence · defined by the following criteria: - Absence of lymph node involvement (ypN0) · assessed on a min. of 15 lymph nodes andFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer
This study is testing a new medicine, ompenaclid, for people with advanced bowel cancer that has a specific genetic change called a RAS mutation. It compares ompenaclid with a dummy pill when added to standard chemotherapy and another drug to see if it helps shrink tumours.
For: such as those associated with RAS mutations.Spain · Belgium · France - AuthorisedTherapeutic confirmatory (Phase III)
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer: A phase III multi-arm, randomized and controlled clinical trial (FOXHIPECT4)
This study is testing different ways to treat advanced colon or upper rectal cancer. It looks at adding a special heated chemotherapy wash to standard treatment during surgery to see if it helps people live longer without the cancer coming back. The aim is to find the best treatment.
Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
This study is looking at new ways to treat advanced oesophageal cancer. We're testing a combination of new drugs and chemotherapy to see if it works better than standard treatments, with a focus on safety and how long people live while on the treatment.
For: Esophageal CarcinomaSpain · Hungary · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
This study looks at a new combination of medicines for a type of stomach or food pipe cancer that has spread. It compares adding the drug pembrolizumab to standard treatment to see if it helps patients live longer without their cancer growing.
For: Gastric or gastroesophageal junction (GEJ) adenocarcinomaIreland · France · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.
This study looks at a new way to treat bowel cancer that has spread only to the liver and can't be removed with surgery. It combines a special radiation treatment with regular cancer medicines to see if it can stop the cancer from growing for longer. It's for adults who have already had some chemotherapy.
For: Liver limited unresectable colorectal cancerItaly - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
This study looks at new drug combinations for advanced stomach or food pipe cancer. It compares a new mix of drugs (Lenvatinib, Pembrolizumab, and chemotherapy) against the usual treatment to see which works best and is safest for patients.
For: Advanced/Metastatic Gastroesophageal AdenocarcinomaSpain · Belgium · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)
This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.
For: Advanced solid tumorsSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
For: Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionGermany · Poland · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
For: Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)Austria · Italy · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)
This study is testing a new medicine, pembrolizumab (Keytruda), alongside standard chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone, especially for cancers that don’t have too much of a protein called HER2.
For: Gastric and gastric esophageal junction (GEJ) adenocarcinomaDenmark · France · Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
For: Gastric and gastroesophageal junction (GEJ) adenocarcinomaPoland · Belgium · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).
For: Solid NeoplasmPoland · France · Austria - Ongoing, recruitingPhase II and Phase III (Integrated)
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
This study is looking at a new way to treat advanced stomach and gullet cancer. It compares a standard chemotherapy treatment with the same treatment plus an extra drug to see if it helps people live longer without their cancer growing. It involves adults with this type of cancer.
For: Locally advanced or metastatic oesogastric adenocarcinomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study
This study is testing new treatments for a type of cancer called anal cancer that has spread. It combines existing chemotherapy with an investigational drug and radiotherapy to see if patients live longer without their cancer getting worse.
For: metastatic squamous cell anal carcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair (ATOMIC)
This study is looking at a new treatment for stage 3 bowel cancer that has a specific genetic feature. It compares standard chemotherapy with chemotherapy plus a new drug called atezolizumab (Tecentriq) to see if the new combination helps people live longer without their cancer coming back.
For: stage III colon adenocarcinoma with deficient MMRGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
This study compares a new drug, avelumab, with standard chemotherapy for advanced bowel cancer that has spread and has specific genetic changes (microsatellite instability). We want to see if avelumab can stop the cancer from growing for longer.
For: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITYFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - AuthorisedTherapeutic confirmatory (Phase III)
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
This study is looking at different chemotherapy treatments for people in the UK who have had pancreatic cancer removed by surgery. It aims to find out which treatment works best to stop the cancer from coming back by comparing standard care with a new way of choosing treatment based on genetic information.
For: Resected pancreatic ductal adenocarcinomaGermany · Sweden - AuthorisedTherapeutic exploratory (Phase II)
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
This study is looking at a new way to treat locally advanced rectal cancer. It combines standard chemotherapy and radiotherapy with a new drug called Durvalumab to see if this combination causes the cancer to completely disappear before surgery.
For: Locally advanced rectal cancerSpain - RecruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal AdenocarcinomaUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - AuthorisedTherapeutic exploratory (Phase II)
Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)
This study looks at different ways to give a common chemotherapy treatment (FOLFIRI) for advanced bowel cancer. Researchers want to see if giving it less often works just as well at keeping the cancer under control, while hopefully making treatment easier for patients.
For: Metastatic colorectal cancerHungary - AuthorisedTherapeutic use (Phase IV)
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial
This study looks at new ways to treat advanced bowel cancer that has specific genetic features. Researchers want to see if combining existing treatments can shrink tumours early and help people live longer, while also improving their quality of life.
For: advanced colorectal cancer with wild-type RAS and right primary tumour location (right-PTL)Italy · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
This study looks at new treatments for advanced stomach or gastro-oesophageal junction cancer that has grown despite earlier chemotherapy. We're testing if adding two new drugs, domvanalimab and zimberelimab, to standard chemotherapy (FOLFIRI) helps patients live longer without their cancer getting worse.
For: stomach cancer · Esophage · gastro-oesophageal junction adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11
This study looks at different ways to give cetuximab with other drugs (FOLFIRI) for advanced bowel cancer that has spread. It wants to see if giving cetuximab continuously or in breaks affects how well the treatment works and patients' quality of life.
For: metastatic colorectal cancerGermany - AuthorisedTherapeutic confirmatory (Phase III)
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old
This study is looking at different ways to treat advanced bowel cancer in people over 75, comparing standard surgery with a plan that tries to avoid major surgery while still aiming for a good outcome. It wants to see which approach works best.
For: Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy · FOLFOX chemotherapy and total mesorectal excision (TME) surgeryFrance - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
This study is looking at a new treatment called ivonescimab, given with standard chemotherapy (FOLFOX), for bowel cancer that has spread. We compare it to another treatment (bevacizumab) also with FOLFOX, to see which works best at stopping the cancer from growing.
For: Metastatic colorectal cancerBelgium · Italy · Spain